Precision Oncology’s Messerschmidt Discusses Cancer Vaccine Development in Biocompare

 

Chief Medical Officer Gerry Messerschmidt authors a new commentary in Biocompare outlining critical success factors toward cancer vaccine development. Messerschmidt counters some high-profile vaccine failures with recent advances that, in fact, have taken us much closer to achieving an effective therapeutic cancer vaccine than ever before.

To read Dr. Messerschmidt’s complete commentary, please click here.